Everolimus [RAD 001], in combination with octreotide long-acting repeatable (LAR), shows promising antitumour activity

By  

Inpharma, Vol. 1, Iss. 1657, 2008-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumors

By Feldman Darren   Turkula Stefan   Ginsberg Michelle   Ishill Nicole   Patil Sujata   Carousso Maryann   Bosl George   Motzer Robert  

Investigational New Drugs, Vol. 28, Iss. 4, 2010-08 ,pp. : 523-528

Springer Publishing Company

Access to resources Recommend Favorite

Phase II Trial of Temozolomide in Patients with Cisplatin-Refractory Germ Cell Tumors

By Varuni Kondagunta G.   Bacik Jennifer   Schwartz Lawrence   Sheinfeld Joel   Bajorin Dean   Vuky Jacqueline   Marion Stephanie   Mazumdar Madhu   Bosl George J.   Motzer Robert J.  

Investigational New Drugs, Vol. 22, Iss. 2, 2004-04 ,pp. : 177-179

Springer Publishing Company

Access to resources Recommend Favorite

Patients with advanced gastric cancer may benefit from treatment with a combination of capecitabine and docetaxel

By  

Inpharma, Vol. 1, Iss. 1442, 2004-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

Phase II trial of bryostatin-1 in combination with cisplatin in patients with recurrent or persistent epithelial ovarian cancer: a California cancer consortium study

By Morgan Robert  

Investigational New Drugs, Vol. 30, Iss. 2, 2012-04 ,pp. : 723-728

Springer Publishing Company

Access to resources Recommend Favorite